PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Patients with advanced penile cancer have a poor prognosis (21% 2-year overall survival from
moment of diagnosis) and high morbidity due to progressive locoregional disease.
Translational studies show high rates of infiltrating immune cells and PD-L1 positivity,
suggesting that immunotherapy may be beneficial in this disease. Atezolizumab, targeting
PD-L1, is active in several cancer types and is generally well-tolerated. This study will
investigate whether atezolizumab can be combined with radiotherapy to control locoregional
lymph node disease. Furthermore, the activity of atezolizumab in advanced penile cancer
patients will be investigated.